ArticleMacromolecular bioscience2019
Peptide Amphiphile Supramolecular Nanostructures as a Targeted Therapy for Atherosclerosis.
Article in Macromolecular bioscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- Combating Reactive Oxygen Species (ROS) with Antioxidant Supramolecular Polymers.ACS applied materials & interfaces · 2025Article
- Therapeutic Supramolecular Polymers: Designs and Applications.Progress in polymer science · 2024Article
- Hydrogels for Gasotransmitter Delivery: Nitric Oxide, Carbon Monoxide, and Hydrogen Sulfide.Macromolecular bioscience · 2024Review
- Nanoparticles in the New Era of Cardiovascular Therapeutics: Challenges and Opportunities.International journal of molecular sciences · 2023Review
- An Overview of the Supramolecular Systems for Gene and Drug Delivery in Tissue Regeneration.Pharmaceutics · 2022Review
- Nanofiber Carriers of Therapeutic Load: Current Trends.International journal of molecular sciences · 2022Review
- Peptide Amphiphile Supramolecular Nanofibers Designed to Target Abdominal Aortic Aneurysms.ACS nano · 2022Article
- Introducing Hyaluronic Acid into Supramolecular Polymers and Hydrogels.Biomacromolecules · 2021Article
- Facilitating functionalization of benzene-1,3,5-tricarboxamides by switching amide connectivity.Organic & biomolecular chemistry · 2021Article
- Self-Assembled Peptide Amphiphile Nanofibers for Controlled Therapeutic Delivery to the Atherosclerotic Niche.Advanced therapeutics · 2021Article
- Enhancing Peptide Biomaterials for Biofabrication.Polymers · 2021Review
- Intravenous Delivery of Lung-Targeted Nanofibers for Pulmonary Hypertension in Mice.Advanced healthcare materials · 2021Article
- Development of novel nanofibers targeted to smoke-injured lungs.Biomaterials · 2021Article
- Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis.Advanced drug delivery reviews · 2021Review
- Nanotechnology for Targeted Therapy of Atherosclerosis.Frontiers in pharmacology · 2021Review
- Design of materials with supramolecular polymers.Progress in polymer science · 2020Review
- Anchoring Supramolecular Polymers to Human Red Blood Cells by Combining Dynamic Covalent and Non-Covalent Chemistries.Angewandte Chemie (International ed. in English) · 2020Article
- Effective atherosclerotic plaque inflammation inhibition with targeted drug delivery by hyaluronan conjugated atorvastatin nanoparticles.Nanoscale · 2020Article
- Development of Fractalkine-Targeted Nanofibers that Localize to Sites of Arterial Injury.Nanomaterials (Basel, Switzerland) · 2020Article
- Application of the Nano-Drug Delivery System in Treatment of Cardiovascular Diseases.Frontiers in bioengineering and biotechnology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
The rising prevalence of cardiovascular disease worldwide necessitates novel therapeutic approaches to manage atherosclerosis. Intravenously administered nanostructures are a promising noninvasive approach to deliver therapeutics that reduce plaque burden. The drug liver X receptor agonist GW3965 (LXR) can reduce atherosclerosis by promoting cholesterol efflux from plaque but causes liver toxicity when administered systemically at effective doses, thus preventing its clinical use. The ability of peptide amphiphile nanofibers containing apolipoprotein A1-derived targeting peptide 4F to serve as nanocarriers for LXR delivery (ApoA1-LXR PA) in vivo is investigated here. These nanostructures are found to successfully target atherosclerotic lesions in a mouse model within 24 h of injection. After 8 weeks of intravenous administration, the nanostructures significantly reduce plaque burden in both male and female mice to a similar extent as LXR alone in comparison to saline-treated controls. Furthermore, they do not cause increased liver toxicity in comparison to LXR treatments, which may be related to more controlled release by the nanostructure. These findings demonstrate the potential of supramolecular nanostructures as safe, effective drug nanocarriers to manage atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.